Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Edwards Lifesciences Corp

Healthcare US EW

85.78USD
1.52(1.80%)

Last update at 2026-03-10T20:01:00Z

Day Range

82.8886.38
LowHigh

52 Week Range

60.5794.87
LowHigh

Fundamentals

  • Previous Close 84.26
  • Market Cap45675.51M
  • Volume6226155
  • P/E Ratio32.18
  • Dividend Yield2.23%
  • EBITDA1717.30M
  • Revenue TTM5819.00M
  • Revenue Per Share TTM9.56
  • Gross Profit TTM 4303.60M
  • Diluted EPS TTM2.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1767.40M 1702.00M 916.70M 1166.50M 761.40M
Minority interest - - - - -
Net income 1521.90M 1503.10M 823.40M 1046.90M 722.20M
Selling general administrative 1567.60M 1493.70M 1228.40M 1242.20M 1088.50M
Selling and marketing expenses - - - - -
Gross profit 4302.00M 3983.60M 3305.70M 3233.60M 2783.40M
Reconciled depreciation 139.60M 134.80M 107.20M 89.30M 77.40M
Ebit 1748.50M 1348.50M 1628.40M 1146.80M 1312.70M
Ebitda 1829.90M 1483.30M 1735.60M 1330.60M 1390.10M
Depreciation and amortization 81.40M 134.80M 107.20M 183.80M 77.40M
Non operating income net other 38.10M 30.10M 34.90M 40.40M 36.00M
Operating income 1748.50M 1348.50M 1628.40M 1146.80M 748.20M
Other operating expenses 3593.20M 3645.70M 3069.70M 3109.30M 2650.10M
Interest expense 19.20M 18.40M 15.80M 20.70M 2.10M
Tax provision 245.50M 198.90M 93.30M 119.60M 39.20M
Interest income 16.30M 1.00M 7.60M 32.20M 32.00M
Net interest income 16.30M -1.00000M 7.60M 11.50M 2.10M
Extraordinary items - - - -2.80000M -15.80000M
Non recurring 76.50M 20.60M 405.40M 98.00M 330.20M
Other items - - - - -
Income tax expense 245.50M 198.90M 93.30M 119.60M 39.20M
Total revenue 5382.40M 5232.50M 4386.30M 4348.00M 3722.80M
Total operating expenses 2512.80M 2396.80M 1989.10M 1994.90M 1710.70M
Cost of revenue 1080.40M 1248.90M 1080.60M 1114.40M 939.40M
Total other income expense net 18.90M 353.50M -711.70000M 19.70M -313.40000M
Discontinued operations - - - - -
Net income from continuing ops 1521.90M 1503.10M 823.40M 1046.90M 722.20M
Net income applicable to common shares 1521.90M 1503.10M 823.40M 1046.90M 722.20M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 8292.50M 8502.60M 7237.10M 6488.10M 5323.70M
Intangible assets 285.20M 323.60M 331.40M 336.50M 343.20M
Earning assets - - - - -
Other current assets 195.90M 237.10M 208.20M 168.00M 131.80M
Total liab 2485.80M 2666.70M 2662.80M 2339.80M 2183.30M
Total stockholder equity 5806.70M 5835.90M 4574.30M 4148.30M 3140.40M
Deferred long term liab - - - - -
Other current liab 311.00M 3.90M 39.30M 6.40M 742.60M
Common stock 646.30M 642.00M 636.40M 218.10M 215.20M
Capital stock 646.30M 642.00M 636.40M 218.10M 215.20M
Retained earnings 7590.00M 6068.10M 4565.00M 3741.60M 2694.70M
Other liab 797.60M 969.60M 1101.20M 784.10M 712.90M
Good will 1164.30M 1167.90M 1173.20M 1167.70M 1112.20M
Other assets 783.10M 357.50M 1247.00M 274.00M 207.60M
Cash 769.00M 862.80M 1183.20M 1179.10M 714.10M
Cash and equivalents 769.00M 862.80M 1183.20M 1179.10M 714.10M
Total current liabilities 1022.40M 1032.30M 893.90M 902.40M 876.60M
Current deferred revenue 484.00M 798.40M 630.90M 690.10M -
Net debt -77.70000M -172.50000M -488.30000M -500.30000M -120.30000M
Short term debt 25.50M 25.50M 27.20M 25.50M 0.00000M
Short long term debt - - - - -
Short long term debt total 691.30M 690.30M 694.90M 678.80M 593.80M
Other stockholder equity -2174.70000M -716.50000M -466.00000M 344.60M 369.00M
Property plant equipment 1725.10M 1638.70M 1395.20M 1060.30M 867.50M
Total current assets 3095.80M 3180.70M 3091.00M 2984.00M 2286.90M
Long term investments 1239.00M 1834.20M 801.60M 585.50M 506.30M
Net tangible assets 4357.20M 4344.40M 3357.70M 2939.60M 1944.40M
Short term investments 446.30M 604.00M 219.40M 337.80M 242.40M
Net receivables 699.10M 664.90M 602.80M 599.10M 537.30M
Long term debt 596.30M 595.70M 595.00M 594.40M 593.80M
Inventory 875.50M 726.70M 802.30M 640.90M 607.00M
Accounts payable 201.90M 204.50M 196.50M 180.40M 134.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -254.90000M -157.70000M -161.10000M -156.00000M -138.50000M
Additional paid in capital - - - - -
Common stock total equity 646.30M 642.00M 636.40M 218.10M 215.20M
Preferred stock total equity - - - - -
Retained earnings total equity 7590.00M 6068.10M 4565.00M 3741.60M 2694.70M
Treasury stock - -2416.90000M -1904.10000M -1278.70000M -1015.40000M
Accumulated amortization - - - - -
Non currrent assets other 299.10M 110.80M 119.60M 101.80M 33.60M
Deferred long term asset charges - - - - -
Non current assets total 5196.70M 5321.90M 4146.10M 3504.10M 3036.80M
Capital lease obligations 95.00M 94.60M 99.90M 84.40M -
Long term debt total 596.30M 595.70M 595.00M 594.40M 593.80M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 252.30M -1335.20000M -101.70000M -158.20000M 329.80M
Change to liabilities -27.00000M 257.20M -137.40000M -20.30000M 34.70M
Total cashflows from investing activities 252.30M -1722.50000M -531.10000M -595.80000M 76.70M
Net borrowings -0.20000M -1.80000M -0.80000M -10.00000M -437.30000M
Total cash from financing activities -1584.50000M -356.30000M -486.90000M -115.60000M -1101.20000M
Change to operating activities -96.90000M -39.80000M 258.30M 9.40M 17.10M
Net income 1521.90M 1503.10M 823.40M 1046.90M 722.20M
Change in cash -94.80000M -332.80000M 15.80M 465.00M -104.20000M
Begin period cash flow 867.40M 1200.20M 1184.40M 714.10M 818.30M
End period cash flow 772.60M 867.40M 1200.20M 1179.10M 714.10M
Total cash from operating activities 1218.20M 1732.10M 1054.30M 1179.40M 926.80M
Issuance of capital stock - - - 160.50M 147.00M
Depreciation 139.60M 134.80M 107.20M 89.30M 77.40M
Other cashflows from investing activities 517.10M -61.50000M -22.40000M -183.20000M -14.40000M
Dividends paid - - - -18.90000M 688.00M
Change to inventory -213.40000M 19.00M -120.60000M -105.40000M -65.70000M
Change to account receivables -84.10000M -112.40000M 283.90M -94.80000M -13.00000M
Sale purchase of stock -1727.10000M -512.80000M -625.40000M -263.30000M -795.50000M
Other cashflows from financing activities 142.80M 163.50M 155.50M 35.00M 1360.60M
Change to netincome -49.10000M -79.60000M 53.30M 198.20M 169.80M
Capital expenditures 264.80M 329.80M 407.30M 278.40M 241.70M
Change receivables -84.10000M -91.10000M 41.90M -88.00000M -28.70000M
Cash flows other operating 1452.20M 1491.80M 1109.90M 1105.60M 739.30M
Exchange rate changes - - - - -6.50000M
Cash and cash equivalents changes -114.00000M -346.70000M 36.30M 468.00M -104.20000M
Change in working capital -421.40000M 145.30M 42.20M -204.30000M -42.60000M
Stock based compensation 126.80M 109.30M 92.60M 81.30M 71.00M
Other non cash items 105.80M -119.00000M 38.30M 154.10M 126.10M
Free cash flow 953.40M 1402.30M 647.00M 901.00M 685.10M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EW
Edwards Lifesciences Corp		 1.52 1.80% 85.78 32.18 27.25 7.85 6.82 7.60 23.41
ABT
Abbott Laboratories		 -2.1 1.86% 110.55 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -7.27 1.99% 358.65 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -1.45 1.59% 89.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -1.94 2.70% 69.96 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corp

One Edwards Way, Irvine, CA, United States, 92614

Key Executives

Name Title Year Born
Mr. Michael A. Mussallem Chairman & CEO 1953
Mr. Scott B. Ullem Corp. VP & CFO 1967
Mr. Donald E. Bobo Jr. Corp. VP of Strategy & Corp. Devel. 1962
Mr. Larry L. Wood Corp. VP of Transcatheter Aortic Valve Replacement 1966
Mr. Jean-Luc Lemercier Corp. VP of Europe, Middle East, Africa, Canada & Latin America 1957
Dr. Todd J. Brinton Corp. VP of Advanced Technology & Chief Scientific Officer NA
Mark Wilterding VP of Investor Relations NA
Mr. Arnold A. Pinkston Corp. VP & Gen. Counsel 1959
Mr. Dirksen J. Lehman Corp. VP of Public Affairs NA
Ms. Christine Z. McCauley Corp. VP of HR 1965

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.